Ph.D., CEO, Biological Dynamics, Inc
Biography
Raj Krishnan, PhD, has pioneered using AC Electrokinetics to directly isolate blood-based nanoparticles. This foundational technology powers Biological Dynamics’ novel isolation platform, Verita™. Since founding Biological Dynamics in 2010, Krishnan has led the company’s efforts to incorporate these unique capabilities into accessible cancer diagnostics to support better care. The company is developing a portfolio of novel oncology products to enable early detection and monitoring in multiple settings – from cancer centers to physician’s offices to patient’s homes.
Clinical Dx Showcase:
Biological Dynamics, Inc
Biological Dynamics is developing novel oncology molecular diagnostic systems for laboratory and point-of-care applications. The company’s technology excels at isolating nanoparticles - such as DNA, RNA, and exosomes - from unprocessed blood-based samples, driving a radically simplified workflow.
Isolation Matters: Oncology, Neuroscience and TB Biomarkers
Biological Dynamics is developing a novel lab-on-a-chip platform, Verita™, that offers a simplified workflow for isolation of blood-based circulating nanoparticles. Raj Krishnan, CEO, will share insights on applications of the technology in oncology, TB and neuroscience.
Session Abstract – PMWC 2020 Silicon Valley
Track 6 - January 22 2.30 P.M.-3.45 P.M.,Track 7 - January 23 1.15 P.M.-1.30 P.M.,Track 6 - January 24 9.00 A.M.-1.15 P.M.
The PMWC 2020 Data Applications in Clinical Diagnostics Showcase will provide a 15-minute time slot for selected organizations, including commercial companies, clinical testing labs, and medical research institutions, to present their latest advancements, insights, applications, and technologies to an audience of clinicians, leading investigators, academic institutions, pharma and biotech, investors, and potential clients. We will learn about new technologies and findings that promise expedited, cost-effective, and accurate clinical diagnosis for early disease detection, treatment decisions, and disease prevention.
